|
Biopharm Knowledge Publishing is developing a series
of expert Guides to key outsourcing issues in the pharmaceutical and
biotechnology industries. EvaluatePharma® Yearbook - Company Performance Tables Benchmark a Changing Market In a fast-changing pharmaceutical market it is vital to be able to measure company performance easily and accurately – find out which companies are winning in the areas that count and which are suffering in changing circumstances. The new EvaluatePharma® Yearbook gives you the information that you need, in context. The Yearbook provides information and data of the highest quality, taken directly from the EvaluatePharma® database and it will enable you to:
All of the detailed information in the Yearbook is put in context by explanations of the new pharmaceutical market place, how it works and how companies perform within it. The Yearbook provides detailed information about the top 150 companies, including:
With 41 tables of detailed EvaluatePharma® information this 140 page report is edited by former Scrip Magazine Journalist Jacky Law. It is essential reading for everybody in the pharmaceutical market from senior executives and corporate strategists, through marketing and sales departments to market analysts and pharmaceutical outsourcing companies. Download the table of contents Download the list of tables £1450 ($2900) For further information about this report contact Marianne O’Neill on +44 (0)1256 336632 or moneill@biopharmkp.comClick here to order Contract Research Annual Review 2008 The Complete Picture of the Contract Research Market The contract research market is booming, growing by 28% last year - far faster than the industry it serves. This review provides a complete picture of the market, looks at trends and developments and explains how they will affect the future of the market. And it includes details of more than 50 mergers, acquisitions and joint ventures. With 37 graphs and 15 tables, this 140-page review includes:
Written by industry experts the Contract Research Annual Review costs just £275 ($545). Download the table of contents Click here to order The Rise of Mid-Sized Pharma What makes mid-sized companies successful – and what big Pharma can learn from them Since the year 2000 mid-sized pharmaceutical companies have out performed their larger rivals – they have grown more rapidly, produced better profits and have performed far better on the world’s stock markets. There are many reasons why this has happened; big pharma is facing a multitude of serious problems that it did not realise were important just a few years ago. Now there are major issues with public perception, an innovation deficit and increased regulation. The lessons for big Pharma are clear and this report provides a challenging analysis of the factors involved, including:
The report, written by former Scrip Magazine journalist Jacky Law is published by Biopharm Knowledge Publishing in association with EvaluatePharma® and includes more than 20 tables of EvaluatePharma® information, clearly defining the market and providing evidence to substantiate the arguments made. Interviews with leading industry experts Jo Pisani of PwC and Mike Ward of Nomura Code also form a key part of the report. This report is essential reading for anyone in the biotech, pharmaceutical and clinical outsourcing industries from corporate management through development and research to marketing and sales. It gives an authoritative, detailed and clear explanation of the issues surrounding mid-sized Pharma and their implications for the market and for the biotech and pharmaceutical industries. Download the table of contents Download the list of EvaluatePharma® tables £795 ($1565) For further information about this report contact Marianne O’Neill on +44 (0)1256 336632 or moneill@biopharmkp.comClick here to order Cardiac Toxicity Cardiac Toxicity – drugs causing heart muscle, valve damage or potentially fatal arrhythmias in patients - has been implicated in 28% of drug withdrawals in the USA over the last 30 years. The significance for patients, regulators and the pharmaceutical industry is immense. If cardiac toxicity is discovered during a drug’s development the programme will, almost invariably, be terminated. If cardiac toxicity is discovered after launch then the drug may be withdrawn or new labelling will almost certainly be required. The consequences for the global pharmaceutical industry can be huge, with major drugs being withdrawn and companies being sued for negligence. But often cardiac events are so rare that they may only be found many years after launch and after thousands, or even millions, of patients have been treated. And when cardiac events do occur the exact mechanism involved may remain a mystery. This unique report covers all aspects of cardiac toxicity, from physiology and pharmacology to regulation by the FDA and EMEA. It looks at:
It will help you to:
The report is edited by Dr Graham Hughes and includes a chapter on the commercial implications written by Yann Bonduelle and Jo Pisani of PwC. Key industry and academic figures have also contributed significant chapters to the report:
This report, published in association with Oxford Cardiac Pharmacology is essential reading for anyone in biotech, pharmaceuticals or contract research. It will appeal to Corporate Management, Development, R&D, Pre-clinical and Clinical Safety, Regulatory Compliance, Quality, Marketing and Sales. It gives an up to date, authoritative, detailed and clear explanation of the issues surrounding cardiac toxicity and its implications for the pharmaceutical market. Download the table of contents Download the introduction £1495 ($2950) For further information about this report contact Marianne O’Neill on +44 (0)1256 336632 or moneill@biopharmkp.comClick here to order Immunogenicity
to Biologics Understanding immunogenicity, a detrimental and potentially dangerous response to therapeutic proteins, is vitally important for the successful development and marketing of biotech drugs. Failure to predict and minimise levels of immunogenicity may have harmful and sometimes disastrous results for both patients and the industry. This comprehensive new report written by leaders in the field, gives you the information you need to understand immunogenicity and to implement relevant safety strategies. The commercial implications are covered in a section written by experts at PricewaterhouseCoopers (PwC). This unique 170-page report includes chapters by the following industry experts: Dr Stephen Swanson, Director, Clinical Immunology,
Amgen Plus an additional chapter on the commercial implications
by PwC experts Jo Pisani and Yann Bonduelle.
Contents include:
This report is essential reading for anyone in biotech, biosimilars and pharmaceuticals, and for contract research. It will appeal to Corporate Management, Development, R&D, Pre-clinical and Clinical Safety, Regulatory Compliance, Quality, Marketing and Sales. It gives an authoritative, detailed and clear explanation of the issues surrounding immunogenicity and its implications for the market and the biotech, biosimilar and pharmaceutical industries. Download the table of contents £1450 ($2900) For further information about this report contact
Marianne O’Neill on +44 (0)1256 336632 or moneill@biopharmkp.com Central
and Core Laboratories Updated, October 2007 The Central and Core Laboratories market is now worth more than $1.5 billion a year and is vital to the successful development of new drugs. It is a truly global business dominated by major players. Choosing the right Central Laboratory and handling the relationship effectively is vital to the successful management of clinical trials, as is the complex business of getting samples from the patient to the laboratory. In a publishing breakthrough this 250 page report – updated October 2007 – gives comprehensive cover the Central Laboratories market, the major companies involved, the processes, including testing and logistics and the future challenges for the market. It is a vital resource for anyone involved in drug development, clinical trials, the central labs market and logistics. Contents include:
The comprehensively-referenced report is published by Biopharm Knowledge Publishing, Part of the Technomark Group and is edited by Dr Graham Hughes, one of the leading experts on pharmaceutical outsourcing and one of the founders of Technomark. Contributors include: Dr Graham Hughes This 250 page report provides a full picture
of a fast-growing industry now worth more than $1 billion and vital
to the success of drug development. It also gives a complete guide
to managing the outsourcing and logistics process. Download the table of contents or moneill@biopharmkp.com Biosimilars - Evolution or Revolution? A detailed guide to the factors that will shape this vital market, including company strategies, comparability, regulation, the implications for clinical trials and legal issues. With a chapter written by PricewaterhouseCoopers looking at the commercial implications for the biotech and pharmaceutical markets The market for biotech drugs grew by 18% last year and now exceeds $50 billion – that’s 10% of the global pharmaceutical market at nearly three times the growth rate. But the first biotech drugs were launched in the mid 1980s and now patents have expired on drugs worth more than $13 billion. Until very recently generic competition was not possible but now in Europe, the EMEA has issued guidelines and the first biosimilar has been approved. In the USA the FDA still has to act, but the direction is becoming clearer. How this market develops will be vital for all the players involved – major pharma, biotechs, generic companies and CROs. This unique, detailed, 200+ page report, includes a chapter on the commercial implications written by Jo Pisani and Yann Bonduelle, Pharmaceutical & Healthcare strategy consultants at PricewaterhouseCoopers. The report will enable you to:
Contents include:
This report is essential reading for anyone in the pharmaceutical, biotech and outsourcing industries from corporate management through development and research to marketing and sales. It gives an authoritative, detailed and clear explanation of the factors that will affect the market for biosimilars and their implications for the market and for the pharmaceutical industry.
£1950 ($3600) For further information about this report, please contact Marianne O'Neill on +44 (0)1256 336632or moneill@biopharmkp.com Click here to order Outsourcing
Chemistry Services Made Easy Pharmaceutical and biotech companies are outsourcing more of their work than ever before – the list includes drug discovery, development, manufacture and marketing. This new report provides a clear, comprehensive guide to the processes involved in outsourcing chemical and biotech development and production. It will help you to: • Understand the rationale for outsourcing As well as the complete guide the report contains in-depth interviews with development service providers and outsourcers to give a real life understanding of the issues from both sides of the fence. And it has a full listing of service providers categorised by services offered and location. Contents include: • Rational for outsourcing This 120 page report is published by Biopharm Knowledge Publishing, part of the Technomark group and costs just £695 ($1290). It is written and edited by Dr Ed Sampler of Charnwood Molecular and Hooshang Zavareh of Chempharmaserve Ltd. DOWNLOAD THE TABLE OF CONTENTS £695 ($1290) For further information about this report, please contact Marianne O'Neill on +44 (0)1256 336632or moneill@biopharmkp.com Click here to order
Clinical
Trial Supply
DOWNLOAD THE TABLE OF CONTENTS 
Click
for PDF file.Price: £595 ($1075) For further information about this report, please contact Marianne O'Neill on +44 (0)1256 336632 or moneill@biopharmkp.com Click here to order |
|
|||
